Are you over 18 and want to see adult content?
More Annotations
A complete backup of amataraphuket.com
Are you over 18 and want to see adult content?
A complete backup of westerncape.gov.za
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://morrisoncenter.com
Are you over 18 and want to see adult content?
A complete backup of https://lloydsaul.com
Are you over 18 and want to see adult content?
A complete backup of https://worldkashmir.org
Are you over 18 and want to see adult content?
A complete backup of https://alphafoodie.com
Are you over 18 and want to see adult content?
A complete backup of https://superphone.io
Are you over 18 and want to see adult content?
A complete backup of https://ericfischl.com
Are you over 18 and want to see adult content?
A complete backup of https://belsimpel.nl
Are you over 18 and want to see adult content?
A complete backup of https://pokerab.com
Are you over 18 and want to see adult content?
A complete backup of https://cine.com
Are you over 18 and want to see adult content?
A complete backup of https://shockwarehouse.com
Are you over 18 and want to see adult content?
A complete backup of https://uniqueworldrecords.com
Are you over 18 and want to see adult content?
Text
chimeric antigen
MEDTRONIC WINS CE MARK FOR SMART INSULIN PEN, GUARDIAN 4 Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor.. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment decisions NEURORX COMPLETES MERGER WITH SPAC, STARTS TRADING ON NeuroRx completes merger with SPAC, starts trading on Nasdaq. NeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp. The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a newsrelease.
INTRANASAL COVID-19 VACCINES COULD BE ON THE HORIZON Image courtesy of AltImmune. All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID MEDTRONIC MUST FACE PAIN-PUMP LAWSUIT Medtronic must face pain-pump lawsuit. A 70-year-old man may proceed with a lawsuit claiming that Medtronic’s SynchroMed II infusion pump is defective and that the company was negligent in manufacturing it. A U.S. District Court judge in West Virginia last week denied Medtronic’s motion to dismiss the lawsuit brought by John DavidBrumfield
NEURORX, TFF PHARMACEUTICALS ENTER FEASIBILITY AGREEMENT NeuroRx and TFF Pharmaceuticals (NSDQ:TFFP) announced a feasibility agreement for the former’s Zyesami therapeutic.. Zyesami (aviptadil, synthetic VIP) materials are set to be delivered to TFF to perform feasibility formulation work and testing in an effort to identify an optimal, long-term, stable formulation of Zyesami into a dry powder form for aerosol delivery directly to the lungs ABBOTT, TANDEM SEAL DEAL TO COMBINE CGM, INSULIN DELIVERY Abbott (NYSE:ABT) and Tandem Diabetes Care (NSDQ:TNDM) announced today that they have completed their agreement to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The deal, announced in October, will combine Abbott's Freestyle Libre CGM with Tandem's t:slim X2 pump to monitor glucose without fingersticks. BD WARNS ON SOME AMBULATORY SYRINGE PUMPS Becton Dickinson (NYSE:BDX) issued a field safety notice in the United Kingdom to warn on an issue with its T34 and T34L (T60) ambulatory syringe pumps. The company was alerted to an issue with the syringe pumps that could cause risk of under-infusion and/or alarm failure, according to the notice published today. Users of the syringe DRUG DELIVERY BUSINESS Retractable Technologies wins $27M federal contract. May 25, 2021 By Nancy Crotti. Retractable Technologies (NYSE:RVP) announced that it has received a government contract worth more than $27.3 million for its syringes. The new contract is the third multi-million-dollar deal that the U.S. Department of Health & Human . SEC LAWSUIT ACCUSES RENOVACARE OF SECURITIES FRAUD The biotech RenovaCare (OTCMKTS: RCAR) announced that it has received a civil complaint from the Securities and Exchange Commission (SEC).. The SEC accuses Harmel S. Rayat, a controlling shareholder and chair of RenovaCare, of orchestrating a secret promotional campaign to elevate the company’s stock price. INTERIUS BIOTHERAPEUTICS RAISES $76M SERIES A Interius BioTherapeutics raises $76M Series A. May 18, 2021 By Sean Whooley. Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generateschimeric antigen
MEDTRONIC WINS CE MARK FOR SMART INSULIN PEN, GUARDIAN 4 Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor.. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment decisions NEURORX COMPLETES MERGER WITH SPAC, STARTS TRADING ON NeuroRx completes merger with SPAC, starts trading on Nasdaq. NeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp. The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a newsrelease.
INTRANASAL COVID-19 VACCINES COULD BE ON THE HORIZON Image courtesy of AltImmune. All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID MEDTRONIC MUST FACE PAIN-PUMP LAWSUIT Medtronic must face pain-pump lawsuit. A 70-year-old man may proceed with a lawsuit claiming that Medtronic’s SynchroMed II infusion pump is defective and that the company was negligent in manufacturing it. A U.S. District Court judge in West Virginia last week denied Medtronic’s motion to dismiss the lawsuit brought by John DavidBrumfield
NEURORX, TFF PHARMACEUTICALS ENTER FEASIBILITY AGREEMENT NeuroRx and TFF Pharmaceuticals (NSDQ:TFFP) announced a feasibility agreement for the former’s Zyesami therapeutic.. Zyesami (aviptadil, synthetic VIP) materials are set to be delivered to TFF to perform feasibility formulation work and testing in an effort to identify an optimal, long-term, stable formulation of Zyesami into a dry powder form for aerosol delivery directly to the lungs ABBOTT, TANDEM SEAL DEAL TO COMBINE CGM, INSULIN DELIVERY Abbott (NYSE:ABT) and Tandem Diabetes Care (NSDQ:TNDM) announced today that they have completed their agreement to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The deal, announced in October, will combine Abbott's Freestyle Libre CGM with Tandem's t:slim X2 pump to monitor glucose without fingersticks. BD WARNS ON SOME AMBULATORY SYRINGE PUMPS Becton Dickinson (NYSE:BDX) issued a field safety notice in the United Kingdom to warn on an issue with its T34 and T34L (T60) ambulatory syringe pumps. The company was alerted to an issue with the syringe pumps that could cause risk of under-infusion and/or alarm failure, according to the notice published today. Users of the syringe CARDINAL HEALTH WINS NEW FDA APPROVAL FOR LYMPHOSEEK Cardinal Health (NYSE:CAH) announced today that the FDA approved its Lymphoseek injection for pediatric use.. Dublin, Ohio-based Cardinal Health touts Lymphoseek, which it acquired from Navidea Biopharmaceuticals (NYSE:NAVB) in November 2016, as the first and only radiopharmaceutical agent specifically designed for targeted lymphatic mapping nad guiding sentinel lymph node biopsies FDA CLASSIFIES NOVO NORDISK INSULIN PEN RECALLS AS CLASS I 17 hours ago · In May, Novo Nordisk announced that it voluntarily recalled 1,468 product samples related to its Levemir, Tresiba, Fiasp, Novolog and Xultophy insulin lines. The products were held at sub-freezing temperatures, prompting the FDA to recently classify the recalls as Class I. FDA uses the Class I designation for situations where there is “a reasonable probability” that a product couldcause
INTRANASAL COVID-19 VACCINES COULD BE ON THE HORIZON Image courtesy of AltImmune. All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID COULD VAXXAS' TINY PATCHES ENABLE A BETTER COVID-19 Invisible to the naked eye and coated with vaccine, the projections can quickly deliver vaccine to immune cells. Vaxxas officials claim the technology can deliver vaccine more efficiently than a needle and syringe. The patch comes in a hockey-puck-shaped applicator with a foil seal. The patch is anchored on a serpentine ring with a powerful INTRAVACC TOUTS PRECLINICAL, NON-HUMAN RESULTS FOR COVID Intravacc is today touting positive pre-clinical results of its SARS-CoV-2 nasal spray vaccine candidate in non-human subjects.. Bilthoven, Netherlands-based Intravacc’s SARS-CoV-2 outer membrane vesicle (OMV)-based recombinant spike protein (rSp) nasal spray candidate was observed in four groups of mice and four groups of hamsters, all of which received two intranasal immunizations on day GLAUKOS COMPLETES ENROLLMENT IN PHASE 3 TRIALS FOR IDOSE Glaukos (NYSE:GKOS) annonced today that it completed enrollment for a Phase 3 clinical program for its iDose TR sustained-release travoprost implant.. San Clemente, Calif.-based Glaukos’ iDose TR implant contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP) through a design that continuously releases therapeutic levels of the CARBON HEALTH ACQUIRES STEADY HEALTH AND ITS DIABETES Carbon Health announced today that it acquired Steady Health and its platform for using continuous glucose monitoring to personalize diabetes care.. San Francisco–based Carbon Health said in a news release that the acquisition accelerates its rollout of a new primary care model designed to integrate its clinic footprint with virtual and hardware-enabled capabilities to create high-quality VIACYTE CLOSES $45M FINANCING FOR STEM CELL-DERIVED TYPE 1 ViaCyte announced today that it closed a $45 million Series D financing tranche to bring the total round to more than $115 million.. San Diego-based ViaCyte said in a news release that proceeds raised in the financing will be earmarked for its advanced portfolio of cell-derived therapies designed to provide a functional cure for patients with type 1 diabetes. ABBOTT, TANDEM SEAL DEAL TO COMBINE CGM, INSULIN DELIVERY Abbott (NYSE:ABT) and Tandem Diabetes Care (NSDQ:TNDM) announced today that they have completed their agreement to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The deal, announced in October, will combine Abbott's Freestyle Libre CGM with Tandem's t:slim X2 pump to monitor glucose without fingersticks.FEATURED ARCHIVES
3M (NYSE:MMM) announced today that it entered into an agreement to sell most of its drug-delivery business to an affiliate of Altaris Capital Partners for approximately $650 million. DRUG DELIVERY BUSINESS Retractable Technologies wins $27M federal contract. May 25, 2021 By Nancy Crotti. Retractable Technologies (NYSE:RVP) announced that it has received a government contract worth more than $27.3 million for its syringes. The new contract is the third multi-million-dollar deal that the U.S. Department of Health & Human . SEC LAWSUIT ACCUSES RENOVACARE OF SECURITIES FRAUD The biotech RenovaCare (OTCMKTS: RCAR) announced that it has received a civil complaint from the Securities and Exchange Commission (SEC).. The SEC accuses Harmel S. Rayat, a controlling shareholder and chair of RenovaCare, of orchestrating a secret promotional campaign to elevate the company’s stock price. INTERIUS BIOTHERAPEUTICS RAISES $76M SERIES A Interius BioTherapeutics raises $76M Series A. May 18, 2021 By Sean Whooley. Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generateschimeric antigen
MEDTRONIC WINS CE MARK FOR SMART INSULIN PEN, GUARDIAN 4 Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor.. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment decisions NEURORX COMPLETES MERGER WITH SPAC, STARTS TRADING ON NeuroRx completes merger with SPAC, starts trading on Nasdaq. NeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp. The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a newsrelease.
INTRANASAL COVID-19 VACCINES COULD BE ON THE HORIZON Image courtesy of AltImmune. All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID MEDTRONIC MUST FACE PAIN-PUMP LAWSUIT Medtronic must face pain-pump lawsuit. A 70-year-old man may proceed with a lawsuit claiming that Medtronic’s SynchroMed II infusion pump is defective and that the company was negligent in manufacturing it. A U.S. District Court judge in West Virginia last week denied Medtronic’s motion to dismiss the lawsuit brought by John DavidBrumfield
NEURORX, TFF PHARMACEUTICALS ENTER FEASIBILITY AGREEMENT NeuroRx and TFF Pharmaceuticals (NSDQ:TFFP) announced a feasibility agreement for the former’s Zyesami therapeutic.. Zyesami (aviptadil, synthetic VIP) materials are set to be delivered to TFF to perform feasibility formulation work and testing in an effort to identify an optimal, long-term, stable formulation of Zyesami into a dry powder form for aerosol delivery directly to the lungs ABBOTT, TANDEM SEAL DEAL TO COMBINE CGM, INSULIN DELIVERY Abbott (NYSE:ABT) and Tandem Diabetes Care (NSDQ:TNDM) announced today that they have completed their agreement to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The deal, announced in October, will combine Abbott's Freestyle Libre CGM with Tandem's t:slim X2 pump to monitor glucose without fingersticks. BD WARNS ON SOME AMBULATORY SYRINGE PUMPS Becton Dickinson (NYSE:BDX) issued a field safety notice in the United Kingdom to warn on an issue with its T34 and T34L (T60) ambulatory syringe pumps. The company was alerted to an issue with the syringe pumps that could cause risk of under-infusion and/or alarm failure, according to the notice published today. Users of the syringe DRUG DELIVERY BUSINESS Retractable Technologies wins $27M federal contract. May 25, 2021 By Nancy Crotti. Retractable Technologies (NYSE:RVP) announced that it has received a government contract worth more than $27.3 million for its syringes. The new contract is the third multi-million-dollar deal that the U.S. Department of Health & Human . SEC LAWSUIT ACCUSES RENOVACARE OF SECURITIES FRAUD The biotech RenovaCare (OTCMKTS: RCAR) announced that it has received a civil complaint from the Securities and Exchange Commission (SEC).. The SEC accuses Harmel S. Rayat, a controlling shareholder and chair of RenovaCare, of orchestrating a secret promotional campaign to elevate the company’s stock price. INTERIUS BIOTHERAPEUTICS RAISES $76M SERIES A Interius BioTherapeutics raises $76M Series A. May 18, 2021 By Sean Whooley. Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generateschimeric antigen
MEDTRONIC WINS CE MARK FOR SMART INSULIN PEN, GUARDIAN 4 Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor.. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment decisions NEURORX COMPLETES MERGER WITH SPAC, STARTS TRADING ON NeuroRx completes merger with SPAC, starts trading on Nasdaq. NeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp. The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a newsrelease.
INTRANASAL COVID-19 VACCINES COULD BE ON THE HORIZON Image courtesy of AltImmune. All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID MEDTRONIC MUST FACE PAIN-PUMP LAWSUIT Medtronic must face pain-pump lawsuit. A 70-year-old man may proceed with a lawsuit claiming that Medtronic’s SynchroMed II infusion pump is defective and that the company was negligent in manufacturing it. A U.S. District Court judge in West Virginia last week denied Medtronic’s motion to dismiss the lawsuit brought by John DavidBrumfield
NEURORX, TFF PHARMACEUTICALS ENTER FEASIBILITY AGREEMENT NeuroRx and TFF Pharmaceuticals (NSDQ:TFFP) announced a feasibility agreement for the former’s Zyesami therapeutic.. Zyesami (aviptadil, synthetic VIP) materials are set to be delivered to TFF to perform feasibility formulation work and testing in an effort to identify an optimal, long-term, stable formulation of Zyesami into a dry powder form for aerosol delivery directly to the lungs ABBOTT, TANDEM SEAL DEAL TO COMBINE CGM, INSULIN DELIVERY Abbott (NYSE:ABT) and Tandem Diabetes Care (NSDQ:TNDM) announced today that they have completed their agreement to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The deal, announced in October, will combine Abbott's Freestyle Libre CGM with Tandem's t:slim X2 pump to monitor glucose without fingersticks. BD WARNS ON SOME AMBULATORY SYRINGE PUMPS Becton Dickinson (NYSE:BDX) issued a field safety notice in the United Kingdom to warn on an issue with its T34 and T34L (T60) ambulatory syringe pumps. The company was alerted to an issue with the syringe pumps that could cause risk of under-infusion and/or alarm failure, according to the notice published today. Users of the syringe CARDINAL HEALTH WINS NEW FDA APPROVAL FOR LYMPHOSEEK 1 day ago · Cardinal Health (NYSE:CAH) announced today that the FDA approved its Lymphoseek injection for pediatric use.. Dublin, Ohio-based Cardinal Health touts Lymphoseek, which it acquired from Navidea Biopharmaceuticals (NYSE:NAVB) in November 2016, as the first and only radiopharmaceutical agent specifically designed for targeted lymphatic mapping nad guiding sentinel lymph node biopsies FDA CLASSIFIES NOVO NORDISK INSULIN PEN RECALLS AS CLASS I 12 hours ago · In May, Novo Nordisk announced that it voluntarily recalled 1,468 product samples related to its Levemir, Tresiba, Fiasp, Novolog and Xultophy insulin lines. The products were held at sub-freezing temperatures, prompting the FDA to recently classify the recalls as Class I. FDA uses the Class I designation for situations where there is “a reasonable probability” that a product couldcause
INTRANASAL COVID-19 VACCINES COULD BE ON THE HORIZON Image courtesy of AltImmune. All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID COULD VAXXAS' TINY PATCHES ENABLE A BETTER COVID-19 Invisible to the naked eye and coated with vaccine, the projections can quickly deliver vaccine to immune cells. Vaxxas officials claim the technology can deliver vaccine more efficiently than a needle and syringe. The patch comes in a hockey-puck-shaped applicator with a foil seal. The patch is anchored on a serpentine ring with a powerful INTRAVACC TOUTS PRECLINICAL, NON-HUMAN RESULTS FOR COVID Intravacc is today touting positive pre-clinical results of its SARS-CoV-2 nasal spray vaccine candidate in non-human subjects.. Bilthoven, Netherlands-based Intravacc’s SARS-CoV-2 outer membrane vesicle (OMV)-based recombinant spike protein (rSp) nasal spray candidate was observed in four groups of mice and four groups of hamsters, all of which received two intranasal immunizations on day GLAUKOS COMPLETES ENROLLMENT IN PHASE 3 TRIALS FOR IDOSE 1 day ago · Glaukos (NYSE:GKOS) annonced today that it completed enrollment for a Phase 3 clinical program for its iDose TR sustained-release travoprost implant.. San Clemente, Calif.-based Glaukos’ iDose TR implant contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP) through a design that continuously releases therapeutic levelsof the
CARBON HEALTH ACQUIRES STEADY HEALTH AND ITS DIABETES Carbon Health announced today that it acquired Steady Health and its platform for using continuous glucose monitoring to personalize diabetes care.. San Francisco–based Carbon Health said in a news release that the acquisition accelerates its rollout of a new primary care model designed to integrate its clinic footprint with virtual and hardware-enabled capabilities to create high-quality VIACYTE CLOSES $45M FINANCING FOR STEM CELL-DERIVED TYPE 1 ViaCyte announced today that it closed a $45 million Series D financing tranche to bring the total round to more than $115 million.. San Diego-based ViaCyte said in a news release that proceeds raised in the financing will be earmarked for its advanced portfolio of cell-derived therapies designed to provide a functional cure for patients with type 1 diabetes. ABBOTT, TANDEM SEAL DEAL TO COMBINE CGM, INSULIN DELIVERY Abbott (NYSE:ABT) and Tandem Diabetes Care (NSDQ:TNDM) announced today that they have completed their agreement to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The deal, announced in October, will combine Abbott's Freestyle Libre CGM with Tandem's t:slim X2 pump to monitor glucose without fingersticks.FEATURED ARCHIVES
3M (NYSE:MMM) announced today that it entered into an agreement to sell most of its drug-delivery business to an affiliate of Altaris Capital Partners for approximately $650 million. DRUG DELIVERY BUSINESS Retractable Technologies wins $27M federal contract. May 25, 2021 By Nancy Crotti. Retractable Technologies (NYSE:RVP) announced that it has received a government contract worth more than $27.3 million for its syringes. The new contract is the third multi-million-dollar deal that the U.S. Department of Health & Human . SEC LAWSUIT ACCUSES RENOVACARE OF SECURITIES FRAUD The biotech RenovaCare (OTCMKTS: RCAR) announced that it has received a civil complaint from the Securities and Exchange Commission (SEC).. The SEC accuses Harmel S. Rayat, a controlling shareholder and chair of RenovaCare, of orchestrating a secret promotional campaign to elevate the company’s stock price. INTERIUS BIOTHERAPEUTICS RAISES $76M SERIES A Interius BioTherapeutics raises $76M Series A. May 18, 2021 By Sean Whooley. Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generateschimeric antigen
MEDTRONIC WINS CE MARK FOR SMART INSULIN PEN, GUARDIAN 4 Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor.. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment decisions NEURORX COMPLETES MERGER WITH SPAC, STARTS TRADING ON NeuroRx completes merger with SPAC, starts trading on Nasdaq. NeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp. The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a newsrelease.
INTRANASAL COVID-19 VACCINES COULD BE ON THE HORIZON Image courtesy of AltImmune. All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID MEDTRONIC MUST FACE PAIN-PUMP LAWSUIT Medtronic must face pain-pump lawsuit. A 70-year-old man may proceed with a lawsuit claiming that Medtronic’s SynchroMed II infusion pump is defective and that the company was negligent in manufacturing it. A U.S. District Court judge in West Virginia last week denied Medtronic’s motion to dismiss the lawsuit brought by John DavidBrumfield
NEURORX, TFF PHARMACEUTICALS ENTER FEASIBILITY AGREEMENT NeuroRx and TFF Pharmaceuticals (NSDQ:TFFP) announced a feasibility agreement for the former’s Zyesami therapeutic.. Zyesami (aviptadil, synthetic VIP) materials are set to be delivered to TFF to perform feasibility formulation work and testing in an effort to identify an optimal, long-term, stable formulation of Zyesami into a dry powder form for aerosol delivery directly to the lungs ABBOTT, TANDEM SEAL DEAL TO COMBINE CGM, INSULIN DELIVERY Abbott (NYSE:ABT) and Tandem Diabetes Care (NSDQ:TNDM) announced today that they have completed their agreement to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The deal, announced in October, will combine Abbott's Freestyle Libre CGM with Tandem's t:slim X2 pump to monitor glucose without fingersticks. BD WARNS ON SOME AMBULATORY SYRINGE PUMPS Becton Dickinson (NYSE:BDX) issued a field safety notice in the United Kingdom to warn on an issue with its T34 and T34L (T60) ambulatory syringe pumps. The company was alerted to an issue with the syringe pumps that could cause risk of under-infusion and/or alarm failure, according to the notice published today. Users of the syringe DRUG DELIVERY BUSINESS Retractable Technologies wins $27M federal contract. May 25, 2021 By Nancy Crotti. Retractable Technologies (NYSE:RVP) announced that it has received a government contract worth more than $27.3 million for its syringes. The new contract is the third multi-million-dollar deal that the U.S. Department of Health & Human . SEC LAWSUIT ACCUSES RENOVACARE OF SECURITIES FRAUD The biotech RenovaCare (OTCMKTS: RCAR) announced that it has received a civil complaint from the Securities and Exchange Commission (SEC).. The SEC accuses Harmel S. Rayat, a controlling shareholder and chair of RenovaCare, of orchestrating a secret promotional campaign to elevate the company’s stock price. INTERIUS BIOTHERAPEUTICS RAISES $76M SERIES A Interius BioTherapeutics raises $76M Series A. May 18, 2021 By Sean Whooley. Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generateschimeric antigen
MEDTRONIC WINS CE MARK FOR SMART INSULIN PEN, GUARDIAN 4 Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor.. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment decisions NEURORX COMPLETES MERGER WITH SPAC, STARTS TRADING ON NeuroRx completes merger with SPAC, starts trading on Nasdaq. NeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp. The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a newsrelease.
INTRANASAL COVID-19 VACCINES COULD BE ON THE HORIZON Image courtesy of AltImmune. All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID MEDTRONIC MUST FACE PAIN-PUMP LAWSUIT Medtronic must face pain-pump lawsuit. A 70-year-old man may proceed with a lawsuit claiming that Medtronic’s SynchroMed II infusion pump is defective and that the company was negligent in manufacturing it. A U.S. District Court judge in West Virginia last week denied Medtronic’s motion to dismiss the lawsuit brought by John DavidBrumfield
NEURORX, TFF PHARMACEUTICALS ENTER FEASIBILITY AGREEMENT NeuroRx and TFF Pharmaceuticals (NSDQ:TFFP) announced a feasibility agreement for the former’s Zyesami therapeutic.. Zyesami (aviptadil, synthetic VIP) materials are set to be delivered to TFF to perform feasibility formulation work and testing in an effort to identify an optimal, long-term, stable formulation of Zyesami into a dry powder form for aerosol delivery directly to the lungs ABBOTT, TANDEM SEAL DEAL TO COMBINE CGM, INSULIN DELIVERY Abbott (NYSE:ABT) and Tandem Diabetes Care (NSDQ:TNDM) announced today that they have completed their agreement to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The deal, announced in October, will combine Abbott's Freestyle Libre CGM with Tandem's t:slim X2 pump to monitor glucose without fingersticks. BD WARNS ON SOME AMBULATORY SYRINGE PUMPS Becton Dickinson (NYSE:BDX) issued a field safety notice in the United Kingdom to warn on an issue with its T34 and T34L (T60) ambulatory syringe pumps. The company was alerted to an issue with the syringe pumps that could cause risk of under-infusion and/or alarm failure, according to the notice published today. Users of the syringe CARDINAL HEALTH WINS NEW FDA APPROVAL FOR LYMPHOSEEK 1 day ago · Cardinal Health (NYSE:CAH) announced today that the FDA approved its Lymphoseek injection for pediatric use.. Dublin, Ohio-based Cardinal Health touts Lymphoseek, which it acquired from Navidea Biopharmaceuticals (NYSE:NAVB) in November 2016, as the first and only radiopharmaceutical agent specifically designed for targeted lymphatic mapping nad guiding sentinel lymph node biopsies FDA CLASSIFIES NOVO NORDISK INSULIN PEN RECALLS AS CLASS I 8 hours ago · In May, Novo Nordisk announced that it voluntarily recalled 1,468 product samples related to its Levemir, Tresiba, Fiasp, Novolog and Xultophy insulin lines. The products were held at sub-freezing temperatures, prompting the FDA to recently classify the recalls as Class I. FDA uses the Class I designation for situations where there is “a reasonable probability” that a product couldcause
COULD VAXXAS' TINY PATCHES ENABLE A BETTER COVID-19 Invisible to the naked eye and coated with vaccine, the projections can quickly deliver vaccine to immune cells. Vaxxas officials claim the technology can deliver vaccine more efficiently than a needle and syringe. The patch comes in a hockey-puck-shaped applicator with a foil seal. The patch is anchored on a serpentine ring with a powerful GLAUKOS COMPLETES ENROLLMENT IN PHASE 3 TRIALS FOR IDOSE 1 day ago · Glaukos (NYSE:GKOS) annonced today that it completed enrollment for a Phase 3 clinical program for its iDose TR sustained-release travoprost implant.. San Clemente, Calif.-based Glaukos’ iDose TR implant contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP) through a design that continuously releases therapeutic levelsof the
INTRAVACC TOUTS PRECLINICAL, NON-HUMAN RESULTS FOR COVID Intravacc is today touting positive pre-clinical results of its SARS-CoV-2 nasal spray vaccine candidate in non-human subjects.. Bilthoven, Netherlands-based Intravacc’s SARS-CoV-2 outer membrane vesicle (OMV)-based recombinant spike protein (rSp) nasal spray candidate was observed in four groups of mice and four groups of hamsters, all of which received two intranasal immunizations on day INTRANASAL COVID-19 VACCINES COULD BE ON THE HORIZON Image courtesy of AltImmune. All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID VIACYTE CLOSES $45M FINANCING FOR STEM CELL-DERIVED TYPE 1 ViaCyte announced today that it closed a $45 million Series D financing tranche to bring the total round to more than $115 million.. San Diego-based ViaCyte said in a news release that proceeds raised in the financing will be earmarked for its advanced portfolio of cell-derived therapies designed to provide a functional cure for patients with type 1 diabetes. FDA SENDS NOVO NORDISK REFUSAL TO FILE LETTER FOR WEEKLY 2 Novo Nordisk. Novo Nordisk announced that the FDA issued a refusal-to-file letter related to its application to expand the label for once-weekly subcutaneous Ozempic (semaglutide). The company had sought to expand the label for a 2.0-mg dose of once-weekly semaglutide to treat type 2 diabetes. It filed the letter on Jan. 20,2021.
ABBOTT, TANDEM SEAL DEAL TO COMBINE CGM, INSULIN DELIVERY Abbott (NYSE:ABT) and Tandem Diabetes Care (NSDQ:TNDM) announced today that they have completed their agreement to combine the former’s glucose-sensing technology with the latter’s insulin delivery systems. The deal, announced in October, will combine Abbott's Freestyle Libre CGM with Tandem's t:slim X2 pump to monitor glucose without fingersticks.FEATURED ARCHIVES
3M (NYSE:MMM) announced today that it entered into an agreement to sell most of its drug-delivery business to an affiliate of Altaris Capital Partners for approximately $650 million. DRUG DELIVERY BUSINESS Retractable Technologies wins $27M federal contract. May 25, 2021 By Nancy Crotti. Retractable Technologies (NYSE:RVP) announced that it has received a government contract worth more than $27.3 million for its syringes. The new contract is the third multi-million-dollar deal that the U.S. Department of Health & Human . SEC LAWSUIT ACCUSES RENOVACARE OF SECURITIES FRAUD The biotech RenovaCare (OTCMKTS: RCAR) announced that it has received a civil complaint from the Securities and Exchange Commission (SEC).. The SEC accuses Harmel S. Rayat, a controlling shareholder and chair of RenovaCare, of orchestrating a secret promotional campaign to elevate the company’s stock price. NEURORX COMPLETES MERGER WITH SPAC, STARTS TRADING ON NeuroRx completes merger with SPAC, starts trading on Nasdaq. NeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp. The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a newsrelease.
DEXCOM TOUTS CGM STUDIES, SHARES DATA ON NEXT-GEN G7 Dexcom touts CGM studies, shares data on next-gen G7. Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM. San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The first study, the INTERIUS BIOTHERAPEUTICS RAISES $76M SERIES A Interius BioTherapeutics raises $76M Series A. May 18, 2021 By Sean Whooley. Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generateschimeric antigen
MEDTRONIC WINS CE MARK FOR SMART INSULIN PEN, GUARDIAN 4 Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor.. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment decisions INTRANASAL COVID-19 VACCINES COULD BE ON THE HORIZON Image courtesy of AltImmune. All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID MEDTRONIC MUST FACE PAIN-PUMP LAWSUIT Medtronic must face pain-pump lawsuit. A 70-year-old man may proceed with a lawsuit claiming that Medtronic’s SynchroMed II infusion pump is defective and that the company was negligent in manufacturing it. A U.S. District Court judge in West Virginia last week denied Medtronic’s motion to dismiss the lawsuit brought by John DavidBrumfield
BD WARNS ON SOME AMBULATORY SYRINGE PUMPS Becton Dickinson (NYSE:BDX) issued a field safety notice in the United Kingdom to warn on an issue with its T34 and T34L (T60) ambulatory syringe pumps. The company was alerted to an issue with the syringe pumps that could cause risk of under-infusion and/or alarm failure, according to the notice published today. Users of the syringe FDA APPROVES J&J'S TREMFYA SELF-INJECTION PEN FOR FDA has approved Johnson & Johnson's patient-controlled injector for Tremfya, a treatment for adults with moderate to severe plaque psoriasis. The self-injection approval may help Tremfya compete with AbbVie's (NYSE:ABBV) Humira pen, which was previously approved for self-injection by psoriasis patients. Made by J&J subsidiary Janssen Pharmaceuticals (Horsham, Penn.), Tremfya is a DRUG DELIVERY BUSINESS Retractable Technologies wins $27M federal contract. May 25, 2021 By Nancy Crotti. Retractable Technologies (NYSE:RVP) announced that it has received a government contract worth more than $27.3 million for its syringes. The new contract is the third multi-million-dollar deal that the U.S. Department of Health & Human . SEC LAWSUIT ACCUSES RENOVACARE OF SECURITIES FRAUD The biotech RenovaCare (OTCMKTS: RCAR) announced that it has received a civil complaint from the Securities and Exchange Commission (SEC).. The SEC accuses Harmel S. Rayat, a controlling shareholder and chair of RenovaCare, of orchestrating a secret promotional campaign to elevate the company’s stock price. NEURORX COMPLETES MERGER WITH SPAC, STARTS TRADING ON NeuroRx completes merger with SPAC, starts trading on Nasdaq. NeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp. The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a newsrelease.
DEXCOM TOUTS CGM STUDIES, SHARES DATA ON NEXT-GEN G7 Dexcom touts CGM studies, shares data on next-gen G7. Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM. San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The first study, the INTERIUS BIOTHERAPEUTICS RAISES $76M SERIES A Interius BioTherapeutics raises $76M Series A. May 18, 2021 By Sean Whooley. Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generateschimeric antigen
MEDTRONIC WINS CE MARK FOR SMART INSULIN PEN, GUARDIAN 4 Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor.. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment decisions INTRANASAL COVID-19 VACCINES COULD BE ON THE HORIZON Image courtesy of AltImmune. All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID MEDTRONIC MUST FACE PAIN-PUMP LAWSUIT Medtronic must face pain-pump lawsuit. A 70-year-old man may proceed with a lawsuit claiming that Medtronic’s SynchroMed II infusion pump is defective and that the company was negligent in manufacturing it. A U.S. District Court judge in West Virginia last week denied Medtronic’s motion to dismiss the lawsuit brought by John DavidBrumfield
BD WARNS ON SOME AMBULATORY SYRINGE PUMPS Becton Dickinson (NYSE:BDX) issued a field safety notice in the United Kingdom to warn on an issue with its T34 and T34L (T60) ambulatory syringe pumps. The company was alerted to an issue with the syringe pumps that could cause risk of under-infusion and/or alarm failure, according to the notice published today. Users of the syringe FDA APPROVES J&J'S TREMFYA SELF-INJECTION PEN FOR FDA has approved Johnson & Johnson's patient-controlled injector for Tremfya, a treatment for adults with moderate to severe plaque psoriasis. The self-injection approval may help Tremfya compete with AbbVie's (NYSE:ABBV) Humira pen, which was previously approved for self-injection by psoriasis patients. Made by J&J subsidiary Janssen Pharmaceuticals (Horsham, Penn.), Tremfya is a BD SURPASSES 2 BILLION ORDERS FOR COVID-19 INJECTION 1 day ago · BD (NYSE:BDX) announced today that orders for its needles and syringes hit 2 billion amid global COVID-19 vaccination efforts. Franklin Lakes, N.J.-based BD’s latest milestone comes less than six months after the company surpassed 1 million orders for vaccine delivery devices in December 2020.. The order total encompasses commitments to governments all over the globe ANANDA SCIENTIFIC ENROLLS FIRST PATIENT IN LIQUID 1 day ago · Ananda Scientific announced today that it enrolled the first patient in a trial evaluating its Liquid Structure delivery system for treating PTSD.. In collaboration with the NYU Grossman School of Medicine, Ananda’s clinical trial will evaluate Nantheia A1002N5S, an investigational drug that uses cannabidiol (CBD) in Ananda’s proprietary Liquid Structure delivery technology to treatpost
VIACYTE CLOSES $45M FINANCING FOR STEM CELL-DERIVED TYPE 1 17 hours ago · ViaCyte announced today that it closed a $45 million Series D financing tranche to bring the total round to more than $115 million.. San Diego-based ViaCyte said in a news release that proceeds raised in the financing will be earmarked for its advanced portfolio of cell-derived therapies designed to provide a functional cure for patients with type 1 diabetes. INTRANASAL COVID-19 VACCINES COULD BE ON THE HORIZON Image courtesy of AltImmune. All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID MEDTRONIC WINS CE MARK FOR SMART INSULIN PEN, GUARDIAN 4 Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor.. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment decisions INTRAVACC TOUTS PRECLINICAL, NON-HUMAN RESULTS FOR COVID Intravacc is today touting positive pre-clinical results of its SARS-CoV-2 nasal spray vaccine candidate in non-human subjects.. Bilthoven, Netherlands-based Intravacc’s SARS-CoV-2 outer membrane vesicle (OMV)-based recombinant spike protein (rSp) nasal spray candidate was observed in four groups of mice and four groups of hamsters, all of which received two intranasal immunizations on day DEXCOM TOUTS CGM STUDIES, SHARES DATA ON NEXT-GEN G7 Dexcom touts CGM studies, shares data on next-gen G7. Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM. San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The first study, the CARBON HEALTH ACQUIRES STEADY HEALTH AND ITS DIABETES Carbon Health announced today that it acquired Steady Health and its platform for using continuous glucose monitoring to personalize diabetes care.. San Francisco–based Carbon Health said in a news release that the acquisition accelerates its rollout of a new primary care model designed to integrate its clinic footprint with virtual and hardware-enabled capabilities to create high-quality TANDEM DIABETES CARE TOUTS STUDY RESULTS FOR INSULIN PUMP Image from Tandem Diabetes. Tandem Diabetes Care (NSDQ:TNDM) today shared real-world data on its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology.. Presenting at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), the company touted immediate and sustained improvements in time-in-range (TIR) observed RESEARCHERS REVERSE DIABETES IN MICE USING NANOSCALE Insulin-secreting beta cells shown in purple are contained within a nano fiber implant. Image courtesy of Wi Wang. Scientists at Washington University (St. Louis) and Cornell University (Ithaca, N.Y.) successfully implanted insulin-secreting cells in mice with type 1 diabetes. The cells proved DRUG DELIVERY BUSINESS Retractable Technologies wins $27M federal contract. May 25, 2021 By Nancy Crotti. Retractable Technologies (NYSE:RVP) announced that it has received a government contract worth more than $27.3 million for its syringes. The new contract is the third multi-million-dollar deal that the U.S. Department of Health & Human . SEC LAWSUIT ACCUSES RENOVACARE OF SECURITIES FRAUD SEC lawsuit accuses RenovaCare of securities fraud. June 1, 2021 By Brian Buntz. The biotech RenovaCare (OTCMKTS: RCAR) announced that it has received a civil complaint from the Securities and Exchange Commission (SEC). The SEC accuses Harmel S. Rayat, a controlling shareholder and chair of RenovaCare, of orchestrating a secretpromotional
MEDTRONIC WINS CE MARK FOR SMART INSULIN PEN, GUARDIAN 4 Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor.. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment decisions DEXCOM TOUTS CGM STUDIES, SHARES DATA ON NEXT-GEN G7 Dexcom touts CGM studies, shares data on next-gen G7. Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM. San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The first study, the NEURORX COMPLETES MERGER WITH SPAC, STARTS TRADING ON NeuroRx completes merger with SPAC, starts trading on Nasdaq. NeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp. The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a newsrelease.
INTERIUS BIOTHERAPEUTICS RAISES $76M SERIES A Interius BioTherapeutics raises $76M Series A. May 18, 2021 By Sean Whooley. Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generateschimeric antigen
FDA SENDS NOVO NORDISK REFUSAL TO FILE LETTER FOR WEEKLY 2 Novo Nordisk. Novo Nordisk announced that the FDA issued a refusal-to-file letter related to its application to expand the label for once-weekly subcutaneous Ozempic (semaglutide). The company had sought to expand the label for a 2.0-mg dose of once-weekly semaglutide to treat type 2 diabetes. It filed the letter on Jan. 20,2021.
DRUG DELIVERY BUSINESS Retractable Technologies wins $27M federal contract. May 25, 2021 By Nancy Crotti. Retractable Technologies (NYSE:RVP) announced that it has received a government contract worth more than $27.3 million for its syringes. The new contract is the third multi-million-dollar deal that the U.S. Department of Health & Human . SEC LAWSUIT ACCUSES RENOVACARE OF SECURITIES FRAUD SEC lawsuit accuses RenovaCare of securities fraud. June 1, 2021 By Brian Buntz. The biotech RenovaCare (OTCMKTS: RCAR) announced that it has received a civil complaint from the Securities and Exchange Commission (SEC). The SEC accuses Harmel S. Rayat, a controlling shareholder and chair of RenovaCare, of orchestrating a secretpromotional
MEDTRONIC WINS CE MARK FOR SMART INSULIN PEN, GUARDIAN 4 Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor.. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment decisions DEXCOM TOUTS CGM STUDIES, SHARES DATA ON NEXT-GEN G7 Dexcom touts CGM studies, shares data on next-gen G7. Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM. San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The first study, the NEURORX COMPLETES MERGER WITH SPAC, STARTS TRADING ON NeuroRx completes merger with SPAC, starts trading on Nasdaq. NeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp. The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a newsrelease.
INTERIUS BIOTHERAPEUTICS RAISES $76M SERIES A Interius BioTherapeutics raises $76M Series A. May 18, 2021 By Sean Whooley. Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generateschimeric antigen
FDA SENDS NOVO NORDISK REFUSAL TO FILE LETTER FOR WEEKLY 2 Novo Nordisk. Novo Nordisk announced that the FDA issued a refusal-to-file letter related to its application to expand the label for once-weekly subcutaneous Ozempic (semaglutide). The company had sought to expand the label for a 2.0-mg dose of once-weekly semaglutide to treat type 2 diabetes. It filed the letter on Jan. 20,2021.
BD SURPASSES 2 BILLION ORDERS FOR COVID-19 INJECTION 1 day ago · BD (NYSE:BDX) announced today that orders for its needles and syringes hit 2 billion amid global COVID-19 vaccination efforts. Franklin Lakes, N.J.-based BD’s latest milestone comes less than six months after the company surpassed 1 million orders for vaccine delivery devices in December 2020.. The order total encompasses commitments to governments all over the globe ANANDA SCIENTIFIC ENROLLS FIRST PATIENT IN LIQUID 1 day ago · Ananda Scientific announced today that it enrolled the first patient in a trial evaluating its Liquid Structure delivery system for treating PTSD.. In collaboration with the NYU Grossman School of Medicine, Ananda’s clinical trial will evaluate Nantheia A1002N5S, an investigational drug that uses cannabidiol (CBD) in Ananda’s proprietary Liquid Structure delivery technology to treatpost
INTRANASAL COVID-19 VACCINES COULD BE ON THE HORIZON Image courtesy of AltImmune. All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID TANDEM DIABETES CARE TOUTS STUDY RESULTS FOR INSULIN PUMP Image from Tandem Diabetes. Tandem Diabetes Care (NSDQ:TNDM) today shared real-world data on its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology.. Presenting at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), the company touted immediate and sustained improvements in time-in-range (TIR) observed INTRAVACC TOUTS PRECLINICAL, NON-HUMAN RESULTS FOR COVID Intravacc is today touting positive pre-clinical results of its SARS-CoV-2 nasal spray vaccine candidate in non-human subjects.. Bilthoven, Netherlands-based Intravacc’s SARS-CoV-2 outer membrane vesicle (OMV)-based recombinant spike protein (rSp) nasal spray candidate was observed in four groups of mice and four groups of hamsters, all of which received two intranasal immunizations on day CARBON HEALTH ACQUIRES STEADY HEALTH AND ITS DIABETES Carbon Health announced today that it acquired Steady Health and its platform for using continuous glucose monitoring to personalize diabetes care.. San Francisco–based Carbon Health said in a news release that the acquisition accelerates its rollout of a new primary care model designed to integrate its clinic footprint with virtual and hardware-enabled capabilities to create high-quality BD TO BUILD $200M FACILITY IN SPAIN FOR PRE-FILLED DRUG BD (NYSE:BDX) announced today that it will build a more than $200 million drug delivery device manufacturing facility in Spain.. The approximately $201.5 million (€165 million) high-tech manufacturing facility in Zaragoza, Spain, is expected to create up RESEARCHERS REVERSE DIABETES IN MICE USING NANOSCALE Insulin-secreting beta cells shown in purple are contained within a nano fiber implant. Image courtesy of Wi Wang. Scientists at Washington University (St. Louis) and Cornell University (Ithaca, N.Y.) successfully implanted insulin-secreting cells in mice with type 1 diabetes. The cells provedFEATURED ARCHIVES
Medtronic (NYSE:MDT) this week launched a cloud-based data management software platform for its Synchromed II drug delivery system. The Efficio platform is designed to allow clinicians to manage targeted drug delivery pump practices to treat patients who have chronic pain, cancer pain and severe spasticity.FEATURED ARCHIVES
Programmable polymer developer Tissium announced that it raised nearly $43 million in a Series B funding round to support expansion. The company’s funding round reached approximately $42.8 million (€38.8 million) and included new investors BNP Paribas Developpement, the European Investment Fund, M&L Investments and ValQuest Partners, along with returning investors Bpifrance, CM-CIC DRUG DELIVERY BUSINESS Retractable Technologies wins $27M federal contract. May 25, 2021 By Nancy Crotti. Retractable Technologies (NYSE:RVP) announced that it has received a government contract worth more than $27.3 million for its syringes. The new contract is the third multi-million-dollar deal that the U.S. Department of Health & Human . SEC LAWSUIT ACCUSES RENOVACARE OF SECURITIES FRAUD SEC lawsuit accuses RenovaCare of securities fraud. June 1, 2021 By Brian Buntz. The biotech RenovaCare (OTCMKTS: RCAR) announced that it has received a civil complaint from the Securities and Exchange Commission (SEC). The SEC accuses Harmel S. Rayat, a controlling shareholder and chair of RenovaCare, of orchestrating a secretpromotional
MEDTRONIC WINS CE MARK FOR SMART INSULIN PEN, GUARDIAN 4 Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor.. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment decisions DEXCOM TOUTS CGM STUDIES, SHARES DATA ON NEXT-GEN G7 Dexcom touts CGM studies, shares data on next-gen G7. Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM. San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The first study, the NEURORX COMPLETES MERGER WITH SPAC, STARTS TRADING ON NeuroRx completes merger with SPAC, starts trading on Nasdaq. NeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp. The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a newsrelease.
INTERIUS BIOTHERAPEUTICS RAISES $76M SERIES A Interius BioTherapeutics raises $76M Series A. May 18, 2021 By Sean Whooley. Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generateschimeric antigen
FDA SENDS NOVO NORDISK REFUSAL TO FILE LETTER FOR WEEKLY 2 Novo Nordisk. Novo Nordisk announced that the FDA issued a refusal-to-file letter related to its application to expand the label for once-weekly subcutaneous Ozempic (semaglutide). The company had sought to expand the label for a 2.0-mg dose of once-weekly semaglutide to treat type 2 diabetes. It filed the letter on Jan. 20,2021.
MEDTRONIC MUST FACE PAIN-PUMP LAWSUIT Medtronic must face pain-pump lawsuit. A 70-year-old man may proceed with a lawsuit claiming that Medtronic’s SynchroMed II infusion pump is defective and that the company was negligent in manufacturing it. A U.S. District Court judge in West Virginia last week denied Medtronic’s motion to dismiss the lawsuit brought by John DavidBrumfield
SMITHS MEDICAL PARTNERS WITH IVENIX ON INFUSION MANAGEMENT Smiths Medical announced today that it partnered with Ivenix on infusion management.. Minneapolis-based Smiths Medical will invest an unspecified amount in the long-term partnership to “revolutionize” infusion management and improve patient safety while meeting the needs of healthcare providers, according to a news release. WEARABLE INFUSION DEVICE MAKER BEXSON BIOMEDICAL APPOINTS Bexson Biomedical announced today that it appointed Sheldon Moberg as its new senior vice president of drug delivery.. Santa Barbara, Calif.–based Bexson said in a news release that Moberg will lead the development of its drug delivery technologies, starting with a wearable infusion device for its BB106 therapy developed in partnership with Stevanato Group. DRUG DELIVERY BUSINESS Retractable Technologies wins $27M federal contract. May 25, 2021 By Nancy Crotti. Retractable Technologies (NYSE:RVP) announced that it has received a government contract worth more than $27.3 million for its syringes. The new contract is the third multi-million-dollar deal that the U.S. Department of Health & Human . SEC LAWSUIT ACCUSES RENOVACARE OF SECURITIES FRAUD SEC lawsuit accuses RenovaCare of securities fraud. June 1, 2021 By Brian Buntz. The biotech RenovaCare (OTCMKTS: RCAR) announced that it has received a civil complaint from the Securities and Exchange Commission (SEC). The SEC accuses Harmel S. Rayat, a controlling shareholder and chair of RenovaCare, of orchestrating a secretpromotional
MEDTRONIC WINS CE MARK FOR SMART INSULIN PEN, GUARDIAN 4 Medtronic (NYSE:MDT) announced today that it received CE mark approvals for its InPen smart insulin pen and its Guardian 4 sensor.. Fridley, Minn.-based Medtronic’s new European approvals cover expanded functionality of the InPen for multiple daily injections (MDI), along with approval for the Guardian 4 sensor that requires no fingersticks for calibration or diabetes treatment decisions DEXCOM TOUTS CGM STUDIES, SHARES DATA ON NEXT-GEN G7 Dexcom touts CGM studies, shares data on next-gen G7. Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM. San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The first study, the NEURORX COMPLETES MERGER WITH SPAC, STARTS TRADING ON NeuroRx completes merger with SPAC, starts trading on Nasdaq. NeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp. The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a newsrelease.
INTERIUS BIOTHERAPEUTICS RAISES $76M SERIES A Interius BioTherapeutics raises $76M Series A. May 18, 2021 By Sean Whooley. Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generateschimeric antigen
FDA SENDS NOVO NORDISK REFUSAL TO FILE LETTER FOR WEEKLY 2 Novo Nordisk. Novo Nordisk announced that the FDA issued a refusal-to-file letter related to its application to expand the label for once-weekly subcutaneous Ozempic (semaglutide). The company had sought to expand the label for a 2.0-mg dose of once-weekly semaglutide to treat type 2 diabetes. It filed the letter on Jan. 20,2021.
MEDTRONIC MUST FACE PAIN-PUMP LAWSUIT Medtronic must face pain-pump lawsuit. A 70-year-old man may proceed with a lawsuit claiming that Medtronic’s SynchroMed II infusion pump is defective and that the company was negligent in manufacturing it. A U.S. District Court judge in West Virginia last week denied Medtronic’s motion to dismiss the lawsuit brought by John DavidBrumfield
SMITHS MEDICAL PARTNERS WITH IVENIX ON INFUSION MANAGEMENT Smiths Medical announced today that it partnered with Ivenix on infusion management.. Minneapolis-based Smiths Medical will invest an unspecified amount in the long-term partnership to “revolutionize” infusion management and improve patient safety while meeting the needs of healthcare providers, according to a news release. WEARABLE INFUSION DEVICE MAKER BEXSON BIOMEDICAL APPOINTS Bexson Biomedical announced today that it appointed Sheldon Moberg as its new senior vice president of drug delivery.. Santa Barbara, Calif.–based Bexson said in a news release that Moberg will lead the development of its drug delivery technologies, starting with a wearable infusion device for its BB106 therapy developed in partnership with Stevanato Group. BD SURPASSES 2 BILLION ORDERS FOR COVID-19 INJECTION 21 hours ago · BD (NYSE:BDX) announced today that orders for its needles and syringes hit 2 billion amid global COVID-19 vaccination efforts. Franklin Lakes, N.J.-based BD’s latest milestone comes less than six months after the company surpassed 1 million orders for vaccine delivery devices in December 2020.. The order total encompasses commitments to governments all over the globe ANANDA SCIENTIFIC ENROLLS FIRST PATIENT IN LIQUID 20 hours ago · Ananda Scientific announced today that it enrolled the first patient in a trial evaluating its Liquid Structure delivery system for treating PTSD.. In collaboration with the NYU Grossman School of Medicine, Ananda’s clinical trial will evaluate Nantheia A1002N5S, an investigational drug that uses cannabidiol (CBD) in Ananda’s proprietary Liquid Structure delivery technology to treatpost
INTRANASAL COVID-19 VACCINES COULD BE ON THE HORIZON Image courtesy of AltImmune. All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID TANDEM DIABETES CARE TOUTS STUDY RESULTS FOR INSULIN PUMP Image from Tandem Diabetes. Tandem Diabetes Care (NSDQ:TNDM) today shared real-world data on its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology.. Presenting at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), the company touted immediate and sustained improvements in time-in-range (TIR) observed INTRAVACC TOUTS PRECLINICAL, NON-HUMAN RESULTS FOR COVID Intravacc is today touting positive pre-clinical results of its SARS-CoV-2 nasal spray vaccine candidate in non-human subjects.. Bilthoven, Netherlands-based Intravacc’s SARS-CoV-2 outer membrane vesicle (OMV)-based recombinant spike protein (rSp) nasal spray candidate was observed in four groups of mice and four groups of hamsters, all of which received two intranasal immunizations on day CARBON HEALTH ACQUIRES STEADY HEALTH AND ITS DIABETES Carbon Health announced today that it acquired Steady Health and its platform for using continuous glucose monitoring to personalize diabetes care.. San Francisco–based Carbon Health said in a news release that the acquisition accelerates its rollout of a new primary care model designed to integrate its clinic footprint with virtual and hardware-enabled capabilities to create high-quality BD TO BUILD $200M FACILITY IN SPAIN FOR PRE-FILLED DRUG BD (NYSE:BDX) announced today that it will build a more than $200 million drug delivery device manufacturing facility in Spain.. The approximately $201.5 million (€165 million) high-tech manufacturing facility in Zaragoza, Spain, is expected to create up RESEARCHERS REVERSE DIABETES IN MICE USING NANOSCALE Insulin-secreting beta cells shown in purple are contained within a nano fiber implant. Image courtesy of Wi Wang. Scientists at Washington University (St. Louis) and Cornell University (Ithaca, N.Y.) successfully implanted insulin-secreting cells in mice with type 1 diabetes. The cells provedFEATURED ARCHIVES
Medtronic (NYSE:MDT) this week launched a cloud-based data management software platform for its Synchromed II drug delivery system. The Efficio platform is designed to allow clinicians to manage targeted drug delivery pump practices to treat patients who have chronic pain, cancer pain and severe spasticity.FEATURED ARCHIVES
Programmable polymer developer Tissium announced that it raised nearly $43 million in a Series B funding round to support expansion. The company’s funding round reached approximately $42.8 million (€38.8 million) and included new investors BNP Paribas Developpement, the European Investment Fund, M&L Investments and ValQuest Partners, along with returning investors Bpifrance, CM-CIC * Skip to primary navigation * Skip to main content * Skip to primary sidebar* Skip to footer
DRUG DELIVERY BUSINESS Search this website Menu* Clinical Trials
* Research & Development * Drug-Device Combinations* FDA
* Pharmaceuticals
* Policy
MAIN CONTENT
*
MEDTRONIC TOUTS REAL-WORLD RESULTS FOR MINIMED 780G INSULIN PUMP*
TANDEM DIABETES CARE TOUTS STUDY RESULTS FOR INSULIN PUMP WITH CLOSED-LOOP TECHNOLOGY*
CARBON HEALTH ACQUIRES STEADY HEALTH AND ITS DIABETES PLATFORM*
DEXCOM TOUTS CGM STUDIES, SHARES DATA ON NEXT-GEN G7*
STUDY SHOWS CGMS BETTER AT CONTROLLING BLOOD SUGAR IN TYPE 2 DIABETES*
MEDTRONIC TOUTS REAL-WORLD RESULTS FOR MINIMED 780G INSULIN PUMP*
TANDEM DIABETES CARE TOUTS STUDY RESULTS FOR INSULIN PUMP WITH CLOSED-LOOP TECHNOLOGY* 1
* 2
* 3
* 4
* 5
DRUG TECH
TANDEM DIABETES CARE TOUTS STUDY RESULTS FOR INSULIN PUMP WITH CLOSED-LOOP TECHNOLOGY Tandem Diabetes Care (NSDQ:TNDM) today shared real-world data on its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology. Presenting at the 14th International Conference on Advanced Technologies and Treatments for … about Tandem Diabetes Care touts study results for insulin pump with closed-loop technology TODAY ON DRUG DELIVERY BUSINESS * Tandem Diabetes Care touts study results for insulin pump with closed-loop technology * Carbon Health acquires Steady Health and its diabetes platform * Researchers reverse diabetes in mice using nanoscale device * Dexcom touts CGM studies, shares data on next-gen G7 * Study shows CGMs better at controlling blood sugar in type 2diabetes
* Medtronic touts real-world results for MiniMed 780G insulin pump * GM Instruments, Sensonics partner on nasal and oral measurementdevices
SPONSORED CONTENT
NOBLE EXPANDS ITS SERVICES FOR ITS CLIENTS INTO HUMAN FACTORS April 5, 2021 By Sponsored Content Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing … about Noble expands its services for its clients intoHuman Factors
More Sponsored Content >>FEATURED POSTS
TANDEM DIABETES CARE TOUTS STUDY RESULTS FOR INSULIN PUMP WITH CLOSED-LOOP TECHNOLOGY June 4, 2021 By Sean Whooley Tandem Diabetes Care (NSDQ:TNDM) today shared real-world data on its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology. Presenting at the 14th International Conference on Advanced Technologies and Treatments for … about Tandem Diabetes Care touts study results for insulin pump with closed-loop technology CARBON HEALTH ACQUIRES STEADY HEALTH AND ITS DIABETES PLATFORM June 4, 2021 By Sean Whooley Carbon Health announced today that it acquired Steady Health and its platform for using continuous glucose monitoring to personalize diabetes care. San Francisco–based Carbon Health said in a news release that the acquisition accelerates its … about Carbon Health acquires Steady Health and its diabetes platform DEXCOM TOUTS CGM STUDIES, SHARES DATA ON NEXT-GEN G7 June 3, 2021 By Sean Whooley Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM. San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & … about Dexcom touts CGM studies, shares data on next-gen G7 STUDY SHOWS CGMS BETTER AT CONTROLLING BLOOD SUGAR IN TYPE 2 DIABETES June 3, 2021 By Sean Whooley Kaiser Permanente is touting a study demonstrating that using continuous glucose monitors offers better blood sugar control for patients with type 2 diabetes. The study found that patients with insulin-treated type 2 diabetes using continuous … about Study shows CGMs better at controlling blood sugar in type 2diabetes
MEDTRONIC TOUTS REAL-WORLD RESULTS FOR MINIMED 780G INSULIN PUMP June 2, 2021 By Sean Whooley Medtronic (NYSE:MDT) today announced positive real-world outcomes for thousands of patients using the MiniMed 780G insulin pump system. Fridley, Minn.-based Medtronic's MiniMed 780G system automates and personalized the delivery of basal insulin … about Medtronic touts real-world results for MiniMed 780G insulin pump FDA ACCEPTS RESUBMITTED NDA FOR XIPERE FROM CLEARSIDE BIOMEDICAL,BAUSCH HEALTH
June 2, 2021 By Sean Whooley Bausch Health (NYSE:BHC) and Clearside Biomedical (NSDQ:CLSD) announced today that the FDA accepted their resubmitted new drug application for Xipere. Clearside Biomedical designed the investigational Xipere triamcinolone acetonide suprachoroidal … about FDA accepts resubmitted NDA for Xipere from Clearside Biomedical, Bausch Health LYRA INKS $135M PARTNERSHIP TO EXPAND CHRONIC RHINOSINUSITIS TREATMENTIN ASIA
June 2, 2021 By Sean Whooley Lyra Therapeutics (NSDQ:LYRA) announced today that it entered into a strategic partnership with LianBio for its LYR-210 treatment for chronic rhinosinusitis. Watertown, Mass.–based Lyra, which develops the LYR-210 therapeutic to be locally … about Lyra inks $135M partnership to expand chronic rhinosinusitis treatment inAsia
SEC LAWSUIT ACCUSES RENOVACARE OF SECURITIES FRAUD June 1, 2021 By Brian Buntz The biotech RenovaCare (OTCMKTS: RCAR) announced that it has received a civil complaint from the Securities and Exchange Commission (SEC). The SEC accuses Harmel S. Rayat, a controlling shareholder and chair of RenovaCare, of orchestrating a … about SEC lawsuit accuses RenovaCare of securities fraud NOVEOME BIOTHERAPEUTICS INKS LICENSING DEAL FOR SIPNOSE DRUG DELIVERYDEVICE
June 1, 2021 By Sean Whooley Noveome Biotherapeutics announced that it entered a commercial license agreement to use SipNose's proprietary drug delivery device. Yokneam, Israel–based SipNose develops its intranasal Cribriform Targeted Device (CT6), which, under the agreement, … about Noveome Biotherapeutics inks licensing deal for SipNose drug deliverydevice
NRX PHARMACEUTICALS TOUTS ZYESAMI RESULTS, SEEKS EUA FOR TREATINGCOVID-19
June 1, 2021 By Sean Whooley NRx Pharmaceuticals (NSDQ:NRXP) announced that it applied for FDA emergency use authorization based on a study of its Zyesami therapeutic. Radnor, Pa.-based NRx Pharmaceuticals, formerly NeuroRx, just last week completed a merger with SPAC Big … about NRx Pharmaceuticals touts Zyesami results, seeks EUA fortreating COVID-19
IN CASE YOU MISSED IT * DarioHealth touts research on digital therapeutics for diabetespatients
* Phillips-Medisize unveils Aria smart autoinjector * Medtronic wins CE mark for smart insulin pen, Guardian 4 sensor * Retractable Technologies wins $27M federal contract * Nanoform, Celanese partner to develop nanoparticle-enabled drugdelivery
* NeuroRx completes merger with SPAC, starts trading on Nasdaq * BD applicators cited in medical kit recall * UC Riverside researchers tout piezoelectric polymer for drugdelivery
* Avalyn Pharma touts study of aerosolized pulmonary fibrosistreatment
* How Fractyl Labs is ‘reversing’ type 2 diabetes to reduce or eliminate insulin injections * Giiant Pharma raises $11M for drug delivery platform forgastroenterology
* Intersect ENT wins CE mark for Propel Contour sinus implant * DarioHealth acquires PsyInnovations for $30M * FDA issues draft clinical trial guidelines for neurostim, other devices to treat diabetes * Glaukos expands microshunt licensing agreement with SantenPharmaceuticals
CLINICAL TRIALS
TANDEM DIABETES CARE TOUTS STUDY RESULTS FOR INSULIN PUMP WITH CLOSED-LOOP TECHNOLOGY Tandem Diabetes Care (NSDQ:TNDM) today shared real-world data on its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology. Presenting at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), the company touted immediate and sustained improvements in time-in-range (TIR) observed in more than 9,000 people with diabetes using the system DEXCOM TOUTS CGM STUDIES, SHARES DATA ON NEXT-GEN G7 Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM. San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The first study, the Mobile study, published in JAMA, observed 175 ethnically and socioeconomically diverse adults (30 years old STUDY SHOWS CGMS BETTER AT CONTROLLING BLOOD SUGAR IN TYPE 2 DIABETES Kaiser Permanente is touting a study demonstrating that using continuous glucose monitors offers better blood sugar control for patients with type 2 diabetes. The study found that patients with insulin-treated type 2 diabetes using continuous glucose monitors (CGMs) typically had better blood sugar control and fewer visits to the emergency room for hypoglycemia. The study MEDTRONIC TOUTS REAL-WORLD RESULTS FOR MINIMED 780G INSULIN PUMP Medtronic (NYSE:MDT) today announced positive real-world outcomes for thousands of patients using the MiniMed 780G insulin pump system. Fridley, Minn.-based Medtronic’s MiniMed 780G system automates and personalized the delivery of basal insulin through adjustments every five minutes for 24 hours a day. It includes an advanced algorithm designed to automatically correct highs every five minutes NOVEOME BIOTHERAPEUTICS INKS LICENSING DEAL FOR SIPNOSE DRUG DELIVERYDEVICE
Noveome Biotherapeutics announced that it entered a commercial license agreement to use SipNose’s proprietary drug delivery device. Yokneam, Israel–based SipNose develops its intranasal Cribriform Targeted Device (CT6), which, under the agreement, was licensed to Noveome to deliver the Pittsburgh-based company’s ST266 biologic to the central nervous systems, according to a news release. CT6 allowsaerosolized
PRIMARY SIDEBAR
Search this website
MEDTECH 100 INDEX
Market Summary > Current Price$106.96
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing. Click for Company Details >> NEED DRUG DELIVERY BUSINESS NEWS IN A MINUTE? WE DELIVER! Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.FOOTER
MASSDEVICE MEDICAL NETWORKMassDevice
DeviceTalks
Medical Tubing & Extrusion Medical Design & OutsourcingMedTech 100 Index
Drug Discovery & Development Pharmaceutical Processing World Medical Design SouringR&D World
DRUG DELIVERY BUSINESS NEWS Subscribe to Drug Delivery’s E-NewsletterAdvertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts Copyright © 2021 · WTWH Media LLC and its licensors. All rightsreserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media. Advertise | PrivacyPolicy | RSS
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0